Compare Johnson & Johnson (JNJ) vs Nu Holdings Ltd (NU) Price & Performance

Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.

Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.

NU stock trades at $13.47, down 2.81% over the past day, with technical indicators signaling a bearish trend. The company reported strong fundamentals, with revenue growing from $3.0B in 2022 to $10.63B in 2025 and net income turning positive to $2.87B. Recent earnings have shown mixed results, with two misses in the last three quarters, but Q2 2026 results are anticipated as a potential catalyst. Analyst consensus remains bullish with a $14.98 price target, though technical weakness persists near support at $13.

The outlook for NU is supported by robust revenue growth and profitability improvements, but near-term risks include competitive pressures and technical bearishness. Upside potential exists if Q2 earnings beat expectations, while failure to meet targets could exacerbate selling pressure. Investors should weigh strong fundamentals against current market sentiment and upcoming earnings.